The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy
Open Access
- 1 October 2001
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 15 (10) , 1537-1543
- https://doi.org/10.1038/sj.leu.2402257
Abstract
The Bcr-Abl fusion protein drives leukemogenesis and can render leukemia cells resistant to conventional chemotherapy. Geldanamycin (GA), a drug which destabilizes Hsp90-associated proteins, depletes cells of Bcr-Abl, an Hsp90 client, but not of Abl. Both HL60 cells transfected with Bcr-Abl and naturally Ph1-positive K562 leukemia cells are resistant to most cytotoxic drugs, but were found to be sensitive to GA. Furthermore, GA sensitized Bcr-Abl-expressing cells to doxorubicin (DOX) and paclitaxel (PTX). In contrast, in parental HL60 cells, 90 nM GA inhibited PARP cleavage, nuclear fragmentation, and cell death caused by 500 ng/ml DOX. Like GA, STI 571 (an inhibitor of the Abl kinase) sensitized Bcr-Abl-expressing cells to DOX. Unlike GA, STI 571 did not antagonize the cytotoxic effects of DOX in parental HL60 cells. These results indicate that sensitization of Bcr-Abl-expressing cells, but not desensitization of HL60 cells, depends on inhibition of Bcr-Abl. Thus, GA differentially affects leukemia cells depending on their Bcr-Abl expression and selectively increases apoptosis in Bcr-Abl-expressing cells.Keywords
This publication has 29 references indexed in Scilit:
- Blockade of the Bcr-Abl Kinase Activity Induces Apoptosis of Chronic Myelogenous Leukemia Cells by Suppressing Signal Transducer and Activator of Transcription 5–Dependent Expression of Bcl-XLThe Journal of Experimental Medicine, 2000
- Reversibility of acute B-cell leukaemia induced by BCR–ABL1Nature Genetics, 2000
- Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemiaJournal of Clinical Investigation, 2000
- Anti-apoptotic oncogenes prevent caspase-dependent and independent commitment for cell deathCell Death & Differentiation, 1998
- Bcl-2-independent Bcr–Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xLOncogene, 1998
- Depletion of p185 erbB2 , Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activityCancer Chemotherapy and Pharmacology, 1997
- Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90.Proceedings of the National Academy of Sciences, 1996
- Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cellsNature Medicine, 1996
- Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation.Proceedings of the National Academy of Sciences, 1994
- Fused transcript of abl and bcr genes in chronic myelogenous leukaemiaNature, 1985